


ABSTRACT OF THE DISCLOSURE

A compound selected from those of formula (I):



in which:

5 **R**₁ represents a group selected from hydrogen, amino, alkyl, alkenyl, aminoalkyl, aryl, arylalkyl, heterocycle, and cycloalkylalkyl, optionally substituted,

W represents oxygen, sulphur, or =N-R', in which R' is as defined in the description,

10 **X**₁, **X**₂ and **X**₃ represent nitrogen or -C-R₆ in which R₆ is as defined in the description,

Y represents oxygen, sulphur, -NH, or -N(C₁-C₆)alkyl,

15 **Z** represents oxygen, sulphur, -NR₇ in which R₇ is as defined in the description, and optionally carbon atom,

n is an integer from 1 to 8 inclusive,


Z₁ represents -CR₈R₉ wherein R₈ and R₉ are as defined in the description,

A represents aromatic or non-aromatic, heterocyclic or non-heterocyclic ring system,

20 **m** is an integer from 0 to 7 inclusive,

 the group(s) **R**₂ is (are) is as defined in the description,

R₃ represents hydrogen, alkyl, alkenyl, alkynyl, or a group of formula :



in which Z₂, B, R₅, P and q are as defined in the description,

25 optionally, the racemic forms thereof, isomers thereof, N-oxydes thereof, and the pharmaceutically acceptable salts thereof, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix metalloprotease.